We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Array Technologies Inc | NASDAQ:ARRY | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 13.06 | 12.00 | 13.28 | 8 | 09:01:24 |
BOULDER, Colo., June 1, 2017 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Operating Officer, Andy Robbins, will present at the Goldman Sachs 38th Annual Global Healthcare Conference. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.
Event: |
Goldman Sachs 38th Annual Global Healthcare Conference |
Presenter: |
Andy Robbins, Chief Operating Officer |
Date: |
Tuesday, June 13, 2017 |
Time: |
10:00 a.m. Pacific Time |
Webcast: |
https://cc.talkpoint.com/gold006/061317a_as/?entity=52_O16UKUL |
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Seven Array-owned or partnered drugs are advancing in registration studies: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), larotrectinib (partnered with Loxo Oncology), tucatinib (partnered with Cascadian Therapeutics) and ipatasertib (partnered with Roche).
CONTACT: |
Tricia Haugeto |
Array BioPharma Inc. | |
303-386-1193 | |
thaugeto@arraybiopharma.com |
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/array-biopharma-to-present-at-the-goldman-sachs-38th-annual-global-healthcare-conference-300466999.html
SOURCE Array BioPharma Inc.
Copyright 2017 PR Newswire
1 Year Array Technologies Chart |
1 Month Array Technologies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions